menu
    • menu
    [{"orgOrder":0,"company":"Kuros Biosciences","sponsor":"XOMA","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"Nivolumab","moa":"TLR9","graph1":"Oncology","graph2":"Phase II","graph3":"Kuros Biosciences","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Intratumoral Injection","sponsorNew":"Kuros Biosciences \/ XOMA Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Kuros Biosciences \/ XOMA Corporation"}]

    Find Clinical Drug Pipeline Developments & Deals by Kuros Biosciences

    Menu

    Kuros Biosciences

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Kuros Biosciences

                            Switzerland arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Kuros Biosciences

                            Switzerland arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vidutolimod,Nivolumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : XOMA

                            Deal Size : $32.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            XOMA Acquires Royalty and Milestone Interest in Checkmate’s Vidutolimod (CMP-001) from Kuros Biosciences

                            Details : Vidutolimod triggers the body’s innate immune system to attack tumors in combination with other therapies. XOMA has acquired all future potential royalties from commercial sales of vidutolimod, which are tiered from high-single to double digits.

                            Brand Name : CMP-001

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            July 15, 2021

                            Lead Product(s) : Vidutolimod,Nivolumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : XOMA

                            Deal Size : $32.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth